Tag Archive for: MED3000

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, is pleased to announce that M8 Pharmaceuticals, Inc (“M8”) has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further fourteen countries throughout the Central and South American region. Read more…

European Patent Office grants Futura Medical patent for MED3000 providing protection to 2040

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that it has been granted allowance of its EU patent which will provide protection for MED3000 until 2040 in all European markets. In all other key ED markets including the US, the Company is continuing to prosecute patent applications to provide […]

Futura Medical plc – Interim Results 2023

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, is pleased to announce its unaudited interim results for the six months ended 30 June 2023 (“H1 2023”). MED3000, under the brand name Eroxon®, is the first pan-European clinically proven topical treatment for Erectile Dysfunction (“ED”) available without the need of a doctor’s prescription […]

Futura Medical Announces Agreement With Haleon To Commercialise MED3000 In The USA

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, focused on sexual health, today announces that it has entered into a ground breaking licensing agreement with Haleon plc (“Haleon”), a world leading consumer healthcare Company for the rights to […]

Futura’s Fast-Acting Topical Gel for the Treatment of Erectile Dysfunction Granted Marketing Authorisation by the US FDA for Over the Counter Sale

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health, today announces that the US Food and Drug Administration (“FDA”) has granted over the counter sale (“OTC”) Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment […]